ORLANDO, Fla., Jan. 22, 2026 /PRNewswire/ — NAVEE, a global smart mobility brand, showcases its latest innovations, the Eagle F1X and Birdie 5X golf push carts, at PGA Show 2026. These products represent NAVEE’s exploration beyond short-range mobility, bringing intelligent technology and scenario-driven design into golf and outdoor leisure spaces.

The PGA Merchandise Show is the world’s premier golf industry event, bringing together top brands, media, and professionals to showcase innovation, set trends, and shape the future of golf.

The Eagle F1X combines a F1 race car–inspired design with advanced smart features. It offers AI vision and UWB-enabled intelligent auto-follow, as well as AI + GPS smart obstacle avoidance. With 40,000+ global course maps, a 5.5-inch full-color touchscreen, and one-button recall within 150 meters, Eagle F1X gives golfers real-time distance insights and effortless control. At just 15 kg and folding in 3 seconds, it delivers performance and portability in one sleek package.

Eagle F1X has already garnered industry attention. It debuted at CES 2026, earning recognition from The Gadgeteer and Yanko Design as Best of CES, reflecting NAVEE’s commitment to design, and intelligent mobility.

The Birdie 5X emphasizes hands-free operation and compact convenience. Building on the brand’s first electric golf push cart, the Birdie 3 series launched in September 2025, its Follow-Me mode is now more responsive. The UWB-powered auto-follow maintains a 2–8 meter distance, automatically adjusting to the golfer’s pace. With a 220Wh battery, Birdie 5X can complete 36 holes on a single charge, while its 4+1 wheel system and dual 130W motors (250W peak) ensure stability across fairways, sand, mud, and slopes up to 25°.

“NAVEE’s goal is to integrate intelligent technology into golf and other outdoor activities, freeing users to focus on the experience while enhancing convenience and performance,” said Jian Lu, the company’s CEO.

Building on years of expertise in smart mobility and world-leading suspension systems, NAVEE has a natural advantage in entering new sectors. The company is now leveraging these core strengths to expand beyond transportation, bringing intelligence, and reliability to golf and other recreational applications.

About NAVEE

NAVEE is a global smart mobility brand focused on system-level engineering and intelligent technology integration. Leveraging automotive-grade design, advanced suspension systems, and AI-enabled control technologies, NAVEE develops high-performance products to support more sustainable and adaptable mobility across urban, recreational, and outdoor scenarios worldwide. Learn more at https://naveetech.com/.

Partnership with menta tech gives venues verified, white-label resale while keeping control of pricing, data and guest relationships.

ORLANDO, Fla., Jan. 22, 2026 /PRNewswire/ — accesso Technology Group (AIM: ACSO), a leading provider of ticketing, commerce, distribution and guest experience technology for live entertainment and attractions, today announced an expanded partnership with menta tech to introduce a venue-controlled, verified secondary ticketing marketplace across its platform.

The partnership enables venues using accesso ShoWare^SM technology to participate in secondary ticketing on their own terms, keeping resale activity in their ecosystem while maintaining control of pricing, customer insights and the guest experience. Rather than relying on 3^rd-party marketplaces, venues can manage fan-to-fan resale directly with built-in verification and pricing guardrails. 

As secondary ticketing continues to grow, many venues lack visibility into resale activity happening outside their official channels. This collaboration offers venues the option to bring resale in-house while applying pricing guardrails, protecting brand consistency and sharing in revenue from resale activity.

“Resale is already happening around our venues whether they participate or not,” said Mike Evenson, Chief Commercial Officer at accesso. “This partnership gives venues a responsible alternative. By combining ShoWare with menta tech’s infrastructure, we allow venues to maintain control and trust while participating in the secondary market on their own terms.”

The secondary marketplace capability integrates directly with accesso ShoWare, allowing venues to activate resale selectively based on event type or demand. Venues gain full visibility into resale pricing and volume while keeping customer relationships and valuable data intact.

Menta tech provides the underlying infrastructure enabling authenticated, white-label resale without introducing a consumer-facing marketplace brand. This ensures venues remain the main point of contact for engagement with guests.

accesso will be exhibiting at INTIX 2026 in Las Vegas from January 26–29, 2026 at Booth #710, where the team will showcase how accesso gives venues greater control over ticketing, including resale.

About accesso Technology Group plc

accesso is the leading global provider of patented and award-winning technology solutions that redefine the guest experience. accesso provides connected ticketing and eCommerce, virtual queuing, restaurant and retail point of sale, distribution, mobile apps and experience management for more than 1,100 venues worldwide. Our technology helps operators streamline operations, increase revenue and improve the guest journey. We deliver a high volume of product enhancements year-round and continuously invest in R&D to help venues and operators adapt to evolving guest needs.

accesso is a public company, listed on AIM: a market operated by the London Stock Exchange. Learn more at accesso.com or follow accesso on X (Twitter), LinkedIn and Facebook.

PARIS, Jan. 22, 2026 /PRNewswire/ — Faithful to its pioneering spirit since its creation in 1954, Clarins continues its commitment to customer-centric innovative beauty. In 2025, the brand takes a new step by launching the AI Skin Observer, its latest technological gem dedicated to advanced skin analysis.

Clarins AI Skin Observer

This new cutting-edge device is currently being deployed in 20 stores worldwide, including John Lewis Oxford Street in London, Printemps Haussmann in Paris, Clarins boutique in Dubai Hills, La Rinascente in Milan, Clarins boutique & spa in Shanghai Jing An Kerry Center, and Macy’s Herald Square in New York.

A simplified web version is also available online on Clarins website in several countries including the US (http://www.clarinsusa.com), the UK (https://www.clarins.co.uk) and France (https://www.clarins.fr).

A true milestone in the beauty industry.

AI serving human expertise: leveraging both biophysical sensors and face pictures with multiple lighting modes, the AI Skin Observer analyzes up to 22 skin parameters, hence providing unique information about the skin, enriching and refining the expertise of the advice offered in-store.

Perfectly integrated in the retail store selling ceremony: taking the form of a mirror, the AI Skin Observer is perfectly integrated on existing consultation tables, a central element in each Clarins point of sale.

A new release from Clarins Beauty Tech.

Latest launch of an ambitious R&D program dedicated to Clarins customer experience innovation, the AI Skin Observer, developed with the support of an ecosystem of start-ups, is the result of years of fundamental research into skin analysis by the Clarins laboratory and the Group’s progress in AI and imaging, particularly within its Beauty Tech division.

A true extension of the manual Skin Check, the AI Skin Observer represents a natural evolution for Clarins brand which has never ceased to combine science, nature and human expertise, and fully embraces Beauty Tech.

The AI Skin Observer is the latest release from Clarins Group Beauty Tech division, following the Lip Oil Factory – enabling on-demand customization of iconic Clarins Lip Oil – and MyBlend LED mask.

Clarins brand General Manager, Katalin Berenyi: “The AI Skin Observer is designed to fit perfectly into our retail space. Through its ease of use, it allows beauty advisors to remain focused on listening to the client and her needs. It extends their expertise by revealing dimensions invisible to the eye, thanks to algorithms leveraging years of research from Clarins laboratory. By combining AI, beauty tech with human touch, beauty consultations are enhanced.”

Clarins group Chief Digital, IT & Business Support Officer, Laurent Malaveille: ” We are very proud of the AI Skin Observer, the latest Beauty Tech release from our innovation lab, and excited by the enthusiastic feedback from both our beauty consultants and the first customers who tested this new service.”

About Clarins

Founded in Paris in 1954 by Jacques Courtin, Clarins is a family-owned global beauty group that has been innovating for more than 70 years to advance responsible beauty. As a result of continuous research, its plant-based products — formulated and manufactured in France — are sold in over 150 countries through 20,000 points of sale. With nearly 95% of sales generated internationally, Clarins is the No. 1* premium skincare brand in Europe and a leading global player in beauty (skincare and make-up), spa, and wellness. The Group has also developed the brand myBlend, built on the concept of holistic beauty, combining targeted skincare, nutri-cosmetics, and beauty tech. Clarins counts more than 8,000 employees across its Paris headquarters, 28 subsidiaries worldwide, two R&D laboratories, and two industrial sites in France. The Group is jointly led by Jonathan Zrihen, President & CEO, together with Dr. Olivier Courtin and his niece Virginie Courtin, representing the second and third generations of the founding family. Guided by its raison d’être — “Making life more beautiful, passing on a more beautiful planet” — Clarins is committed to sustainable innovation, with over 80% of ingredients of natural origin and a wide range of initiatives to protect nature and care for people. https://www.groupeclarins.com/

*Source: NPD BeautyTrends®, Europe 5 (France, Germany, United Kingdom, Italy, Spain), luxury Skin Care market (products sold in perfumeries and department stores), value sales (€), for the period 3rd January 2022 to 1st January 2023.

Press contacts

France

Image Sept – Marie Artzner – Anne Auchatraire – Caroline Simon – clarins@image7.fr – +33 1 53 70 74 70

USA

Melissa Reidhead – melissa.reidhead@clarins.com and Lucas Petry – lucas.petry@clarins.com

UK

Shoshana Gillis – shoshana.gillis@clarins.com – +44 207 307 6792

China

Derek Hu – derek.hu@clarins.com – +86 186 0166 7400

Italy

Francesca Silva – Francesca.Silva@clarins.com and F.A Studio – f.andreuzzi@fa-studio.eu – c.gorla@fa-studio.eu

UAE

Jala Dia – Jala.Dia@clarins.com

AI Clarins Skin Observer

• CEPI to provide up to USD 30 million to support development of MSD’s Zaire ebolavirus vaccine
• Collaboration addresses manufacturing complexity and cold-chain challenges to improve yield and thermostability
• Partnership aims to expand affordable and sustainable vaccine access in low- and middle-income countries

INCHEON, South Korea, Jan. 22, 2026 /PRNewswire/ — SK bioscience announced that it is advancing the development of a Zaire ebolavirus vaccine under a new collaboration supported by the Coalition for Epidemic Preparedness Innovations (CEPI).

The announcement follows a funding agreement between CEPI and global pharmaceutical company MSD to support continued development of a Zaire ebolavirus vaccine. Under the agreement, CEPI will provide up to USD 30 million in funding to MSD, which will allocate the funding to its development partners, including SK bioscience and Hilleman Laboratories—a joint venture between MSD and Wellcome, a global charitable foundation focused on health research—to carry out key research, manufacturing process improvement and clinical development activities.

The collaboration builds on MSD’s WHO-prequalified Zaire ebolavirus vaccine and focuses on updating the existing manufacturing process, which is complex and requires ultra-low temperature storage. These requirements pose logistical challenges in the remote, low-resource settings where Zaire ebolavirus outbreaks most often occur. By improving manufacturing yield and enhancing the thermostability of the vaccine, the project aims to support more affordable, accessible, and sustainable vaccine supply, subject to regulatory review and public health requirements.

Under the collaboration, Hilleman Laboratories —will lead the clinical development of the updated vaccine. SK bioscience, together with IDT Biologika, will develop the updated drug substance manufacturing process and the associated drug product. As a key implementation partner in the CEPI-backed public health initiative, SK bioscience will leverage its vaccine manufacturing expertise and infrastructure, as well as its collaboration with IDT Biologika. Through this role, the company aims to contribute to improving vaccine affordability, accessibility, and long-term sustainability in low- and middle-income countries.

Zaire ebolavirus is responsible for frequent and unpredictable Ebola outbreaks and is associated with a survival rate of around 50%. Recent outbreaks reported in parts of the Democratic Republic of the Congo and other countries have underscored the continued global risk posed by the virus, particularly in areas with limited healthcare access and logistics infrastructure.

Dr. Richard Hatchett, CEO of CEPI, said, “In a single decade the world has transformed Ebola from a global emergency to a disease that can be stopped in its tracks – and now CEPI’s support will help to enable a sustainable and accessible supply of MSD’s Zaire ebolavirus vaccine for years to come at a more affordable price. This deal brings together longstanding partners of CEPI with longstanding partners of MSD to boost global defences against one of the deadliest pathogens known to humankind, helping to save lives.”

Jaeyong Ahn, CEO of SK bioscience, said, “Addressing deadly infectious diseases such as Ebola requires strong global collaboration. Through this CEPI-supported partnership, SK bioscience will continue to play a critical role in improving Zaire ebolavirus vaccine manufacturing and supply, contributing meaningfully to global health preparedness.”

SK bioscience has established a strong track record of collaboration with global health organizations, including CEPI, the Gates Foundation, and the International Vaccine Institute (IVI). By leveraging its integrated capabilities across development, manufacturing, and supply, the company continues to expand its role as a global partner in public health–driven vaccine initiatives.

About SK bioscience

SK bioscience is an innovative vaccine and biotech company, committed to vaccine development and manufacturing to enable more equitable access to vaccines around the world. Leveraging strengths on cutting-edge technologies, SK bioscience has been dedicated to promoting human health from prevention to cure across the globe. With the cooperation of domestic and international governments, regulatory agencies, healthcare providers, doctors, and medical experts, all of the SK colleagues are passionately committed to providing high-quality vaccines to those who need them and better public healthcare solutions.

– SK bioscience Website
– SK bioscience Linkedin

Contact
SK bioscience Communications Team
Changhyun Jin (jin99@sk.com)  
Muncheol. Kim (MC|_kim@sk.com)

SINGAPORE, Jan. 22, 2026 /PRNewswire/ — Toku Ltd. (“Toku” or the “Company“), a Singapore-incorporated customer experience (CX) technology company, today commenced trading on the Catalist Board of the Singapore Exchange Securities Trading Limited (“SGX-ST“), following the successful completion of its initial public offering (“IPO“).

The Company’s shares opened at S$0.260, reached an intraday high of S$0.305, and closed at S$0.285, with trading beginning on a “ready” basis at 9:00 a.m. SGT under the ticker symbol TKU.

The IPO comprised 65,000,000 Invitation Shares at an offer price of S$0.25 per share, consisting of 2,000,000 Public Offer Shares and 63,000,000 Placement Shares. The Invitation raised total gross proceeds of S$16.25 million, giving the Company a post-IPO market capitalisation of approximately S$142.56 million, based on its enlarged share capital.

Commenting on the Company’s listing, Thomas Laboulle, Founder and CEO of Toku, said, “Debuting on SGX Catalist is a significant step in Toku’s evolution as an enterprise software company, as we accelerate our mission to transform how enterprises manage customer interactions. As a public company, we are sharpening our focus on execution, governance and long-term value creation. We will continue to invest in end-to-end innovation across our technology and solution stack, strengthening our ability to deliver smarter, faster, and fully compliant solutions to our customers located across the globe. This milestone gives us the platform and discipline to scale responsibly as customer expectations and regulatory requirements continue to rise across markets.”

Mrs Lim Hwee Hua, Non-Independent Non-Executive Chairman of Toku, said: “The successful listing marks an important milestone for Toku and is a testament to the team’s focus, discipline and execution. Going public carries significant responsibility, reinforcing our commitment to transparency, sound governance, and long-term value. I am pleased to be part of Toku’s journey as it continues to focus on creating meaningful impact for customers across diverse industries.”

“We are proud to have worked with Toku on its Singapore listing and the strong interest from investors reflects the market’s confidence in Toku’s business and strategy. With access to public markets, enhanced profile, brand recognition and credibility, Toku is well positioned to attract new talent, deepen customer relationships, expand into new markets and scale internationally.  We look forward to continuing our partnership with Toku.” said Mark Liew, CEO, PrimePartners. 

“We are pleased to support Toku in its listing as a co-placement agent. Its highly scalable business model enables global growth and coupled with the team’s dynamism, it is an exciting AI-centric growth story to watch. We look forward to bringing more high quality homegrown companies to market this year,” said Jason Saw, Group Head of Investment Banking, CGS International Securities.

Headquartered in Singapore, Toku provides a cloud-native CX platform that enables enterprises and public-sector organisations to manage customer interactions across voice, chat, email and digital channels within a single integrated environment. Designed for complex, multi-market operations, the platform combines communications infrastructure with AI capabilities such as transcription, summarisation and conversation analytics, while supporting deployment across commercial cloud, private data centres and hybrid environments to meet regulatory, linguistic and operational requirements.

Proceeds from the IPO will be used to support continued investment in Toku’s technology platform, expansion of its partner ecosystem, geographic growth, and general corporate purposes, in line with the Company’s stated strategy.

-END-

About Toku

Headquartered in Singapore, Toku Ltd. (“Toku“) is a cloud-native, AI-powered customer experience platform purpose-built for enterprises operating in complex, multi-market environments. With deep roots in the APAC region and an expanding global footprint, Toku’s modular 360° CX Platform orchestrates customer interactions across voice, chat, email and digital channels while managing regulatory, linguistic and infrastructure complexity at scale.

Built on end-to-end ownership of its technology stack, from carrier-grade connectivity to AI applications, Toku delivers enterprise-grade security, reliability and deployment flexibility across commercial cloud, private data centres and hybrid environments. Its AI capabilities include transcription, summarisation, sentiment analysis, conversation analytics and governed virtual agents, designed to integrate seamlessly with enterprise systems and customer data.

Trusted by leading enterprises and public-sector organisations, Toku helps organisations streamline operations, scale customer engagement and deliver consistent experiences across fragmented markets.

For more information about Toku, visit toku.co

NUREMBERG, Germany, Jan. 22, 2026 /PRNewswire/ — The toy world will gather in Nuremberg from 27 to 31 January for an extraspecial event: the Spielwarenmesse, celebrating its 75^th anniversary together with retailers, manufacturers and the media. As a leading B2B event, it brings the industry together and consolidates its importance as a central platform for business development, inspiration and personal encounters. To mark the anniversary, the organiser, Spielwarenmesse eG, is setting new content priorities, promoting dialogue on future topics and turning the entire exhibition center into a lively stage for the industry.

Christian Ulrich, Member of the Executive Board at Spielwarenmesse eG (Spokesperson), promises plenty of highlights for the 75th Spielwarenmesse, including the ToyAward nominees.

Global relevance

The success story of the Spielwarenmesse reaches a special milestone with its 75^th edition. In front of Entrance Mitte, the ‘Walk of Play’ exhibition invites visitors to discover the most important stages in the history of the fair. What began in 1949 with the decision to found the fair quickly developed into the international gathering for the whole industry. ‘More than ever, the Spielwarenmesse stands for the global market, but also for specialisation and a global network with year-round contacts,’ says Christian Ulrich, Member of the Executive Board at Spielwarenmesse eG (Spokesperson). Specialist retailers and buyers – from traditional toy retailers to online platforms and large chain stores – benefit from a diverse range of products from 2,313 exhibitors from 68 countries. These include 488 new companies that are specifically looking to establish new business relationships at the Spielwarenmesse. Spanning 18 halls and 13 product groups, the event showcases the entire spectrum of the toy world. The anniversary will be celebrated throughout the entire exhibition grounds; exhibitors have prepared more than 30 activities, including selfie spots, interactive stations and musical performances. 

Action areas with fresh ideas

The strategically placed Specials at the Spielwarenmesse provide orientation for the new financial year. In the foyer at Entrance Mitte, the two ToyTrends exemplify pioneering drive in the toy world. ‘AI Loves (to) Play’ showcases toys that use AI tools or impart knowledge about them, while ‘Creative Mindfulness’ focuses on creative and craft skills right through to the finished object. Right next door, the Toys for Kidults area invites visitors to try things out and talk shop. According to market research company Circana, the product area addresses enormous market potential: in the USA, spending on toys for consumers aged 12 and over will reach US$13.4 billion (+12%) between October 2024 and September 2025, and in Europe €5.7 billion (+14%). Visitors will also find forward-looking products in Hall 3A in the newly designed StartupArea. Here, 44 exhibitors from 16 countries will present their creative ideas – including 22 newcomers from Germany. The New Product Gallery will showcase more than 130 different innovations, while the ToyAward, awarded across six categories, draws additional attention to winners and nominees. The award ceremony will take place on Wednesday at 11 am in the Toy Business Forum. In Hall 7A, the Special for the Sports, Leisure, Outdoor category will provide a dynamic atmosphere filled with test areas and activities. 

Deepening specialist knowledge

The Spielwarenmesse is about more than just products – it imparts industry knowledge and thrives on personal exchange. The Toy Business Forum in Hall 3A offers in-depth specialist knowledge with presentations on retail and toy trends, digitalisation, artificial intelligence, sustainability and kidults. Daily lunch breaks with music and food trucks also create space for conversations in a relaxed atmosphere. On the Wednesday, the Value of Play Conference will celebrate its premiere at the Spielwarenmesse, highlighting various facets of play value together with experts from 8.30 to 10.30 am in the Toy Business Forum. For model car fans, Thursday at 4.30 pm at the same location has a special experience in store: With the induction ceremony into the Model Car Hall of Fame, hobbyDB, the world’s largest Diecast community, honours the pioneers of the model vehicle industry. Another target group will find what they are looking for in the NCC West foyer: the LicenseLounge, which focuses on the licensing business as a strong growth driver, and the LicenseTalks event series provides important market insights. On the Friday, the Game Inventors Convention (NCC Mitte, Level 1) will provide a platform for creative minds from the gaming scene – with 156 participants from 22 countries.

An industry in party mood

In addition to product diversity and knowledge transfer, networking is part of the DNA of the Spielwarenmesse. Numerous formats create space for exchange in a relaxed atmosphere. New this year is Let’s Connect! – Toy Community Meetup in Hall 2. Spielwarenmesse participants have the opportunity to get together daily between 12 pm and 4 pm in informal sessions based on unifying subject areas. The exclusive ToyNight on the first day of the fair brings all exhibitors together under the motto ‘Welcome to the Future’. The 15 exhibitors who were there from the very beginning will also be honoured in this festive setting. On the Thursday evening, the RedNight will create a lively party atmosphere with stand parties. ToyCity Nuremberg is also involved in the anniversary celebrations: illuminations of the Imperial Castle and the Frauentor Tower will underline the festive atmosphere.

‘For the 75^th time, the Spielwarenmesse is the central gathering for the industry: people from all over the world come together in Nuremberg to discover trends, take advantage of business opportunities and experience the unique “Spirit of Play”. We look forward to celebrating this anniversary with all participants – and look forward to a successful future with optimism,’ Christian Ulrich sums up.

BURLINGTON, Mass., Jan. 22, 2026 /PRNewswire/ — PAQ Therapeutics, a clinical-stage oncology company developing novel targeted protein degradation therapies for KRAS-driven cancers, today announced the closing of a Series B extension, bringing the company’s total Series B financing to $77 million, and the dosing of the first patient in a Phase 1 clinical trial evaluating PT0511, the company’s pan-KRAS degrader.

The Series B extension builds on PAQ’s previously announced Series B financing, with participation from existing as well as new investors, and further strengthens the company’s balance sheet to advance multiple clinical programs. Proceeds from the financing will support the ongoing Phase 1 development of PT0253, PAQ’s KRAS G12D degrader, as well as the clinical advancement of PT0511.

“Completing this Series B extension and dosing the first patient in our PT0511 Phase 1 study represent important milestones for PAQ,” said Nan Ji, PhD, Chief Executive Officer of PAQ Therapeutics. “Together, these achievements highlight our continued execution against a multi-program clinical strategy and our focus on addressing significant unmet need across KRAS-driven cancers.”

PT0511 is a pan-KRAS degrader designed to target multiple oncogenic KRAS variants. The Phase 1 study is a first-in-human, open-label, dose-escalation trial evaluating the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of PT0511 in patients with advanced solid tumors harboring KRAS alterations.

“The initiation of clinical dosing with PT0511 expands our clinical portfolio beyond single-mutation KRAS targeting,” said Andrew Krivoshik, MD, PhD, Chief Medical Officer of PAQ Therapeutics. “A pan-KRAS degradation approach has the potential to address key limitations for patients observed with existing KRAS- or pan-RAS inhibitor therapies.”

PAQ continues to advance a differentiated KRAS pipeline by leveraging targeted protein degradation to achieve deep and selective suppression of oncogenic signaling, while maintaining favorable safety and combinability profiles.

About PAQ Therapeutics
PAQ Therapeutics is a clinical-stage biotechnology company developing best- and first-in-class KRAS degraders for lethal cancers lacking effective treatment options.